Aquestive Therapeutics enters the week with short sellers pressing harder against a stock that just lost 10% in five sessions — and the borrow market is nearly as tight as it gets.
The most striking development is the sudden surge in short interest. SI jumped nearly 18% in a single day on September 10, reaching 20.9% of the free float — up 53% from a month ago. That's a substantial build in a very short window. Days to cover sits at 7.15, meaning shorts would need over a week of average volume to unwind. The ORTEX short score has moved to 80.6, ticking up sharply from 78.8 earlier in the week, reflecting the combination of high SI, rising borrow demand, and the near-total absence of available shares to lend.
The borrow picture is where this story gets most interesting. For most of August and into early September, availability ran below 1% — meaning for every 100 shares already lent, fewer than one share remained in the pool. That's essentially a fully seized lending market. As of September 10, availability had loosened marginally to 8%, after sitting at 0.18% just the day before. The 52-week low was 0.056%. Cost to borrow, at 1.49%, is up 22% on the week — still low in absolute terms, but moving in the same direction as SI. Options traders are reading the setup differently: the put/call ratio is 0.40, well below its 20-day average of 0.73. That's nearly a full standard deviation toward calls, suggesting the options market is skewed bullish even as short sellers pile in. The two camps are pointing in opposite directions.
The Street remains constructive on paper. The consensus is Buy across six analysts, with a mean price target of $9.33 — implying roughly 95% upside from the current $4.78. The most recent analyst action was HC Wainwright reiterating Buy with a $10 target in late August, though coverage broadly has been quiet since then. Bulls point to the FDA's decision not to require an Advisory Committee meeting for Anaphylm, the no-needle epinephrine product, as removing a key overhang. Bears focus on pipeline execution risk, negative free cash flow, and the likelihood of a capital raise. Factor scores back up the bull case on one dimension: EPS momentum ranks in the 93rd percentile over 30 days and the 88th over 90 days, with EPS surprise in the 86th percentile. But the short score ranks in the 4th percentile and days-to-cover in the 6th — signals that reflect how aggressively the short community is positioned against the stock.
Insider activity adds a layer of context, though not alarm. The CEO, Daniel Barber, exercised options in early September — a compensation mechanism, not a conviction buy. His open-market sales in July and August, conducted under a pre-arranged 10b5-1 plan, are similarly routine. Net insider activity over 90 days runs to roughly -109,000 shares at a net value of around -$482,000, concentrated in planned sales. The largest institutional holder, Bratton Capital, holds 7.8% of shares with no recent change reported. BlackRock added 560,000 shares as recently as August 31, bringing its stake to 6.4%.
Earnings are next scheduled for November 4. The two most recent prints saw the stock fall on the day — down 3.6% in August and 1.4% in an earlier August event — before recovering modestly over the following five sessions. The next print is therefore less about near-term catalysts and more about whether the FDA's Anaphylm review timeline provides any incremental clarity before year-end.
See the live data behind this article on ORTEX.
Open AQST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
